BMS grows its fibrosis portfolio | Chemical & Engineering News
Volume 94 Issue 45 | p. 15 | Concentrates
Issue Date: November 14, 2016

BMS grows its fibrosis portfolio

Department: Business
Keywords: pharmaceuticals, Bristol-Myers Squibb, NASH

Bolstering its growing portfolio of fibrosis treatments, Bristol-Myers Squibb has paid $100 million upfront for access to Nitto Denko’s siRNA molecules targeting heat shock protein 47. Nitto Denko’s lead HSP47 inhibitor, which blocks a protein responsible for regulating collagen synthesis and deposition, is in Phase Ib studies to treat advanced liver fibrosis caused by nonalcoholic steatohepatitis. BMS has in recent years assembled a pipeline of fibrosis assets through deals that include options to buy Galecto Biotech and Promedior.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment